Hormetic response of resveratrol against cardioprotection

B. Juhász, Subhendu Mukherjee, Dipak K. Das

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Resveratrol, a grape- and red wine-derived polyphenolic phytoalexin, shows diverse health benefits including cardioprotection. Recent studies implicate that resveratrol displays hormetic action, protecting the cells at a lower dose while killing them at relatively higher doses. Because such hormetic behaviour may have a significant impact on epidemiological and clinical studies, the present study sought to determine dose-response curves for resveratrol action. In parallel, another resveratrol formulation was tested, namely, Longevinex (Resveratrol Partners LLC, USA). A group of rats were force-fed three different doses of resveratrol or Longevinex (2.5 mg/kg, 25 mg/kg and 100 mg/kg) for up to 30 days, while the control group was only given placebo. The results showed hormesis for pure resveratrol, which was cardioprotective at lower doses and detrimental for higher doses, but surprisingly Longevinex did not display any hormetic action. In the concentration range studied, Longevinex remained cardioprotective even at 100 mg/100 g body weight - a dose that killed 100% of the hearts when tested with pure resveratrol. To further test whether Longevinex doses are beneficial for other animal species, Longevinex was gavaged to a group of rabbits for six months, and showed exactly the same degree of cardioprotection. Cardioprotection was examined in isolated working hearts subjected to 30 min of ischemia followed by 2 h of reperfusion; left ventricular performance and infarct size was also examined. It appears that Longevinex does not show any hormetic action, while resveratrol clearly does.

Original languageEnglish
JournalExperimental and Clinical Cardiology
Volume15
Issue number4
Publication statusPublished - Dec 2010

Fingerprint

Hormesis
resveratrol
Vitis
Insurance Benefits
Wine
Reperfusion
Epidemiologic Studies
Ischemia
Placebos
Body Weight
Rabbits
Control Groups
Clinical Studies
phytoalexins

Keywords

  • Dose response
  • Hormesis
  • Longevinex
  • Resveratrol

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)
  • Physiology

Cite this

Hormetic response of resveratrol against cardioprotection. / Juhász, B.; Mukherjee, Subhendu; Das, Dipak K.

In: Experimental and Clinical Cardiology, Vol. 15, No. 4, 12.2010.

Research output: Contribution to journalArticle

Juhász, B. ; Mukherjee, Subhendu ; Das, Dipak K. / Hormetic response of resveratrol against cardioprotection. In: Experimental and Clinical Cardiology. 2010 ; Vol. 15, No. 4.
@article{3e48c52d365242d89a10a79c42a9a942,
title = "Hormetic response of resveratrol against cardioprotection",
abstract = "Resveratrol, a grape- and red wine-derived polyphenolic phytoalexin, shows diverse health benefits including cardioprotection. Recent studies implicate that resveratrol displays hormetic action, protecting the cells at a lower dose while killing them at relatively higher doses. Because such hormetic behaviour may have a significant impact on epidemiological and clinical studies, the present study sought to determine dose-response curves for resveratrol action. In parallel, another resveratrol formulation was tested, namely, Longevinex (Resveratrol Partners LLC, USA). A group of rats were force-fed three different doses of resveratrol or Longevinex (2.5 mg/kg, 25 mg/kg and 100 mg/kg) for up to 30 days, while the control group was only given placebo. The results showed hormesis for pure resveratrol, which was cardioprotective at lower doses and detrimental for higher doses, but surprisingly Longevinex did not display any hormetic action. In the concentration range studied, Longevinex remained cardioprotective even at 100 mg/100 g body weight - a dose that killed 100{\%} of the hearts when tested with pure resveratrol. To further test whether Longevinex doses are beneficial for other animal species, Longevinex was gavaged to a group of rabbits for six months, and showed exactly the same degree of cardioprotection. Cardioprotection was examined in isolated working hearts subjected to 30 min of ischemia followed by 2 h of reperfusion; left ventricular performance and infarct size was also examined. It appears that Longevinex does not show any hormetic action, while resveratrol clearly does.",
keywords = "Dose response, Hormesis, Longevinex, Resveratrol",
author = "B. Juh{\'a}sz and Subhendu Mukherjee and Das, {Dipak K.}",
year = "2010",
month = "12",
language = "English",
volume = "15",
journal = "Experimental and Clinical Cardiology",
issn = "1205-6626",
publisher = "Pulsus Group Inc.",
number = "4",

}

TY - JOUR

T1 - Hormetic response of resveratrol against cardioprotection

AU - Juhász, B.

AU - Mukherjee, Subhendu

AU - Das, Dipak K.

PY - 2010/12

Y1 - 2010/12

N2 - Resveratrol, a grape- and red wine-derived polyphenolic phytoalexin, shows diverse health benefits including cardioprotection. Recent studies implicate that resveratrol displays hormetic action, protecting the cells at a lower dose while killing them at relatively higher doses. Because such hormetic behaviour may have a significant impact on epidemiological and clinical studies, the present study sought to determine dose-response curves for resveratrol action. In parallel, another resveratrol formulation was tested, namely, Longevinex (Resveratrol Partners LLC, USA). A group of rats were force-fed three different doses of resveratrol or Longevinex (2.5 mg/kg, 25 mg/kg and 100 mg/kg) for up to 30 days, while the control group was only given placebo. The results showed hormesis for pure resveratrol, which was cardioprotective at lower doses and detrimental for higher doses, but surprisingly Longevinex did not display any hormetic action. In the concentration range studied, Longevinex remained cardioprotective even at 100 mg/100 g body weight - a dose that killed 100% of the hearts when tested with pure resveratrol. To further test whether Longevinex doses are beneficial for other animal species, Longevinex was gavaged to a group of rabbits for six months, and showed exactly the same degree of cardioprotection. Cardioprotection was examined in isolated working hearts subjected to 30 min of ischemia followed by 2 h of reperfusion; left ventricular performance and infarct size was also examined. It appears that Longevinex does not show any hormetic action, while resveratrol clearly does.

AB - Resveratrol, a grape- and red wine-derived polyphenolic phytoalexin, shows diverse health benefits including cardioprotection. Recent studies implicate that resveratrol displays hormetic action, protecting the cells at a lower dose while killing them at relatively higher doses. Because such hormetic behaviour may have a significant impact on epidemiological and clinical studies, the present study sought to determine dose-response curves for resveratrol action. In parallel, another resveratrol formulation was tested, namely, Longevinex (Resveratrol Partners LLC, USA). A group of rats were force-fed three different doses of resveratrol or Longevinex (2.5 mg/kg, 25 mg/kg and 100 mg/kg) for up to 30 days, while the control group was only given placebo. The results showed hormesis for pure resveratrol, which was cardioprotective at lower doses and detrimental for higher doses, but surprisingly Longevinex did not display any hormetic action. In the concentration range studied, Longevinex remained cardioprotective even at 100 mg/100 g body weight - a dose that killed 100% of the hearts when tested with pure resveratrol. To further test whether Longevinex doses are beneficial for other animal species, Longevinex was gavaged to a group of rabbits for six months, and showed exactly the same degree of cardioprotection. Cardioprotection was examined in isolated working hearts subjected to 30 min of ischemia followed by 2 h of reperfusion; left ventricular performance and infarct size was also examined. It appears that Longevinex does not show any hormetic action, while resveratrol clearly does.

KW - Dose response

KW - Hormesis

KW - Longevinex

KW - Resveratrol

UR - http://www.scopus.com/inward/record.url?scp=79952565234&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952565234&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:79952565234

VL - 15

JO - Experimental and Clinical Cardiology

JF - Experimental and Clinical Cardiology

SN - 1205-6626

IS - 4

ER -